一名难治性原发性纵隔B细胞淋巴瘤患者接受纳武单抗成功治疗后出现重度中性粒细胞减少。
High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma.
作者信息
Wright Zachary, Brown Alexander
机构信息
Department of Hematology/Oncology, Keesler Medical Center, Keesler AFB, Biloxi, MS; and.
Department of Hematology/Oncology, San Antonio Military Medical Center, Fort Sam Houston, TX.
出版信息
Blood Adv. 2017 Jul 17;1(17):1306-1308. doi: 10.1182/bloodadvances.2017008607. eCollection 2017 Jul 25.
Abstract
Autoimmune neutropenia is a rare side effect of nivolumab which may respond to antibody-based therapies.Nivolumab can lead to durable complete remission in primary mediastinal B-cell lymphoma refractory to multiple lines of therapy.
摘要
自身免疫性中性粒细胞减少是纳武单抗的一种罕见副作用，可能对基于抗体的治疗有反应。纳武单抗可使经多线治疗难治的原发性纵隔B细胞淋巴瘤实现持久的完全缓解。
相似文献
1
High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma.
Blood Adv. 2017 Jul 17;1(17):1306-1308. doi: 10.1182/bloodadvances.2017008607. eCollection 2017 Jul 25.
2
Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review.
Cancer Manag Res. 2020 Jul 27;12:6311-6316. doi: 10.2147/CMAR.S254007. eCollection 2020.
3
Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
Int J Hematol. 2017 Jul;106(1):141-145. doi: 10.1007/s12185-017-2181-9. Epub 2017 Jan 17.
4
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.
5
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.
6
Is chest CT sufficient for follow-up of primary mediastinal B-cell lymphoma in remission?
AJR Am J Roentgenol. 2002 Jan;178(1):165-7. doi: 10.2214/ajr.178.1.1780165.
7
Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Eur J Haematol. 2011 Feb;86(2):117-23. doi: 10.1111/j.1600-0609.2010.01552.x. Epub 2010 Dec 29.
8
9
Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
Bone Marrow Transplant. 2002 Mar;29(6):473-7. doi: 10.1038/sj.bmt.1703401.
10
Complete remission following recombinant interferon alpha-2a in a patient with diffuse large B cell cutaneous lymphoma.
Nouv Rev Fr Hematol (1978). 1989;31(4):315-6.
引用本文的文献
1
Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study.
Front Pharmacol. 2023 Oct 31;14:1213608. doi: 10.3389/fphar.2023.1213608. eCollection 2023.
2
Successful Steroid Treatment of Pembrolizumab-induced Agranulocytosis That Developed after Splenectomy in a Patient with Non-small-cell Lung Cancer.
Intern Med. 2023 Jul 15;62(14):2113-2121. doi: 10.2169/internalmedicine.0278-22. Epub 2022 Nov 30.
3
Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy.
Diagnostics (Basel). 2022 Aug 29;12(9):2091. doi: 10.3390/diagnostics12092091.
4
Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report.
Respir Med Case Rep. 2021 Jun 1;33:101439. doi: 10.1016/j.rmcr.2021.101439. eCollection 2021.
5
No need to hesitate: immune-related neutropenia and thrombocytopenia that improved by corticosteroids.
Respirol Case Rep. 2021 Jun 3;9(7):e00799. doi: 10.1002/rcr2.799. eCollection 2021 Jul.
6
Nivolumab plus gemcitabine, dexamethasone, and cisplatin chemotherapy induce durable complete remission in relapsed/refractory primary mediastinal B-cell lymphoma: a case report and literature review.
J Int Med Res. 2020 Aug;48(8):300060520945075. doi: 10.1177/0300060520945075.
7
Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect.
BMC Cancer. 2020 Apr 14;20(1):300. doi: 10.1186/s12885-020-06763-y.
8
Severe pembrolizumab-associated neutropenia after CD34 selected allogeneic hematopoietic-cell transplantation for multiple myeloma.
Bone Marrow Transplant. 2018 Aug;53(8):1065-1068. doi: 10.1038/s41409-018-0142-4. Epub 2018 Mar 7.
本文引用的文献
1
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8.
2
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.
3
Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
Hum Pathol. 2016 Aug;54:17-24. doi: 10.1016/j.humpath.2016.03.005. Epub 2016 Apr 1.
4
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
5
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
6
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
7
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20.
8
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.
9
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.
N Engl J Med. 2013 Apr 11;368(15):1408-16. doi: 10.1056/NEJMoa1214561.
10
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
Zotero 插件